Qnexa, an experimental weight-loss drug developed by Vivus, has showed that it can reduce sleep apnea, the company confirmed last Thursday.
While the drug is marketed as a weight-loss drug, experts say that its sleep apnea applications can expand its market.
Vivus conducted a 28-week study on 45 obese patients who were suffering from sleep apnea and obstructive sleep apnea.
Treatment of Qnexa led to a significant drop in the number of apnea events for the patients.
However, there were minor side effects, like dry lips, altered taste, and sinus infections.
Vivus says that it is happy about drug’s effects on sleep apnea and plans to invest in more studies about the drug’s effects on the condition.